Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

REGN· Manufacturing· Fiscal year ends in December

CEO pay in FY2024Stock -18.9% in FY2024

Leonard S. Schleifer, M.D., Ph.D. is the CEO of Regeneron Pharmaceuticals and was paid $6.8M in FY2024 (Dec), down 17%.

Pay$100 in the stock at the end of FY20 → $147
CEO pay is from each Regeneron Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives6

See all
  1. 1Daniel P. Van PlewFY2024
  2. 2Andrew J. Murphy, Ph.D.FY2024
  3. 3Leonard S. Schleifer, M.D., Ph.D.FY2024
  4. 4George D. Yancopoulos, M.D., Ph.D.FY2024
  5. 5Christopher FenimoreFY2024
  6. 6Joseph J. LaRosaNot disclosed

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Regeneron Pharmaceuticals paid its 6 named executives $37.2M in total in FY2024 (Dec). CEO Leonard S. Schleifer, M.D., Ph.D. was paid $6.8M of that.

Name
Daniel P. Van PlewExecutive Vice President and General Manager, Industrial Operations and Product Supply
Andrew J. Murphy, Ph.D.Executive Vice President, Co-Chief Scientific Officer
Leonard S. Schleifer, M.D., Ph.D.Board co-Chair, President and Chief Executive Officer
George D. Yancopoulos, M.D., Ph.D.Ph.D. Board co-Chair, President and Chief Scientific Officer
Christopher FenimoreExecutive Vice President, Finance and Chief Financial Officer6Not disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers11

See all

The FY2025 (Dec) proxy of Regeneron Pharmaceuticals names 11 peer companies for pay. Among Regeneron Pharmaceuticals and these peers, CEO pay was the lowest of 8 and total shareholder return was 5th highest of 8.

8th highest of 8in Regeneron Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:

$7.3M$36.7M

5th highest of 8in Regeneron Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:

$105$671

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Activity

No new filings about this company in the feed.

Filings20

See all
Current report8-KSep 30, 2026—
Current report8-KJun 17, 2026—
Proxy statementDEF 14AApr 24, 2026FY2025
Annual report10-KFeb 4, 2026FY2025
Current report8-KJun 18, 2025—
Proxy statementDEF 14AApr 29, 2025FY2024